Indeed, by using a surrogate CAR with affinity to murine FLT3, rituximab-mediated depletion of FLT3 CAR T cells after AML eradication enables bone marrow recovery without compromising leukemia remission (101). This evidence concerns the gene FLT3 and acute myeloid leukemia.